QTTB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Q32 Bio Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 15.68 USD
3.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 99.4% above the Trend Line and sits at 64.1% of its 52-week range. The latest completed week returned 3.5%, after a 19.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 40/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 63 out of 100
Latest Close 15.68 USD 31 Jul 2026
1W Return 3.5% latest completed week
4W Return 19.8% short-term follow-through
12W Return 192.0% quarterly tape
Trend Breadth 84.6% 44 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • The trend backdrop is active with a 44-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.5% Latest completed week; four-week move 19.8%. Indicator stack 92/72 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 40/100 conviction; expected move 20.9%. News sentiment 53/100 40 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 99.4% above the Trend Line and sits at 64.1% of its 52-week range. The latest completed week returned 3.5%, after a 19.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9212-week average 0.82

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 19.8% over four weeks, 192.0% over 12 weeks, and 684.0% over one year. The current trend has remained active for 44 consecutive weeks.

Performance by holding period

1W3.5%
4W19.8%
12W192.0%
26W304.1%
52W684.0%
Active trend streak44 weeks
Active weeks in one year44
Trend breadth84.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.21Latest activity-pressure read.
Pressure change-0.6%Four-week change in activity pressure.
Leadership168.42Latest relative-leadership reading.
RS change9.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value14/100Relative valuation strength. Underlying universe rank 87; rank 1 is best.
Quality77/100Profitability and accounting quality. Underlying universe rank 24; rank 1 is best.
Momentum100/100Medium-term price momentum. Underlying universe rank 1; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
13.5x
Price divided by trailing earnings.
Price / sales
8.4x
Market value relative to trailing revenue.
EV / EBITDA
18.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-6.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.3%
Gross profit retained from each unit of revenue.
Operating margin
40.5%
Operating profit retained from revenue.
Free-cash-flow margin
-51.0%
Free cash flow generated from revenue.
Return on invested capital
177.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-2.3%
Net share repurchases relative to market value.
Shareholder yield
-2.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

QTTB shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.60, expected move of 20.9%, and Sharemaestro trend signal active.

Conviction40/100
Expected move20.9%
Put/call volume0.60
Pressure32
Speculation1
Volatility96
Trend agreement65
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 40 relevant articles.

7 positive · 30 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move20.9%Nearest-chain priced movement where available.
52-week drawdown-33.5%Distance below the 52-week high.
13-week volatility26.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+90.5%Week of 29 May.
Worst week-20.8%Week of 10 Apr.
Latest week+3.5%Week of 31 Jul.

Shape of recent returns

Strong gains12
Modest gains3
Flat weeks0
Modest losses4
Sharp losses7
Recent vol26.0%13-week weekly-return volatility.
Base vol21.0%52-week weekly-return volatility.
Up/down split26/24Count of positive and negative weeks in the 52-week window.
Average skew19.3% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape62/100

Trend, activity pressure, participation, and risk combine to a 62/100 tape read.

 Indicator analysis88/100

Latest 12-week confirmation: trend 12/12, activity pressure 11/12, relative leadership 12/12.

Activity pressure 0.92; No reversal markers Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 79; Small Cap Core rank 90 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options60/100

QTTB shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.60, expected move of 20.9%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 20.9% Sentiment53/100

Weighted news tone is neutral across 40 relevant articles.

Q32 Bio Inc. Revenue Breakdown – NASDAQ:QTTB Insiders50/100

No recent insider transaction evidence is stored.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202615.68 USD3.5%7.86 USD13.42 USD1.21168.422.7MOn
24 Jul 202615.15 USD0.7%7.46 USD13.47 USD1.19172.613.3MOn
17 Jul 202615.05 USD34.3%7.06 USD13.53 USD1.20178.5041.9MOn
10 Jul 202611.21 USD-14.4%6.65 USD13.55 USD1.07107.934.7MOn
3 Jul 202613.09 USD-0.6%6.38 USD13.59 USD1.21154.191.6MOn
26 Jun 202613.17 USD10.7%6.05 USD13.61 USD1.28169.251.9MOn
19 Jun 202611.90 USD-5.9%5.69 USD13.62 USD1.27143.131.4MOn
12 Jun 202612.64 USD-3.6%5.36 USD13.65 USD0.94175.682.7MOn
5 Jun 202613.11 USD18.6%5.01 USD13.69 USD0.60205.804.2MOn
29 May 202611.05 USD90.5%4.65 USD13.74 USD0.20158.4023.8MOn
22 May 20265.80 USD-7.9%4.37 USD13.78 USD-0.1345.161.6MOn
15 May 20266.30 USD17.3%4.28 USD13.86 USD0.1762.321.3MOn
8 May 20265.37 USD6.5%4.17 USD13.94 USD0.3840.621.1MOn
1 May 20265.04 USD-19.0%4.11 USD14.02 USD0.6041.451.4MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.